Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer (BEACON CRC)
A Multicenter, Randomized, Open-label, 3-Arm Phase 3 Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer
Sponsor: Merck KGaA, Darmstadt, Germany
Listed as NCT02928224, this PHASE3 trial focuses on BRAF V600E-mutant Metastatic Colorectal Cancer and remains completed. Sponsored by Merck KGaA, Darmstadt, Germany, it has been updated 40 times since 2016, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
40 versions recorded-
Dec 2025 — Present [monthly]
Completed PHASE3
-
Sep 2025 — Dec 2025 [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2024 — Jul 2024 [monthly]
Completed PHASE3
▶ Show 35 earlier versions
-
Jun 2023 — Jan 2024 [monthly]
Completed PHASE3
-
Apr 2023 — Jun 2023 [monthly]
Completed PHASE3
-
Feb 2023 — Apr 2023 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Dec 2022 — Feb 2023 [monthly]
Active Not Recruiting PHASE3
-
Oct 2022 — Dec 2022 [monthly]
Active Not Recruiting PHASE3
-
Sep 2022 — Oct 2022 [monthly]
Active Not Recruiting PHASE3
-
Apr 2022 — Sep 2022 [monthly]
Active Not Recruiting PHASE3
-
Jan 2022 — Apr 2022 [monthly]
Active Not Recruiting PHASE3
-
Dec 2021 — Jan 2022 [monthly]
Active Not Recruiting PHASE3
-
Mar 2021 — Dec 2021 [monthly]
Active Not Recruiting PHASE3
-
Feb 2021 — Mar 2021 [monthly]
Active Not Recruiting PHASE3
-
Jan 2021 — Feb 2021 [monthly]
Active Not Recruiting PHASE3
-
Aug 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE3
-
Jan 2020 — Aug 2020 [monthly]
Active Not Recruiting PHASE3
-
Jul 2019 — Jan 2020 [monthly]
Active Not Recruiting PHASE3
-
Feb 2019 — Jul 2019 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Jan 2019 — Feb 2019 [monthly]
Recruiting PHASE3
-
Sep 2018 — Jan 2019 [monthly]
Recruiting PHASE3
-
Aug 2018 — Sep 2018 [monthly]
Recruiting PHASE3
-
Jun 2018 — Aug 2018 [monthly]
Recruiting PHASE3
-
May 2018 — Jun 2018 [monthly]
Recruiting PHASE3
-
Mar 2018 — May 2018 [monthly]
Recruiting PHASE3
-
Jan 2018 — Mar 2018 [monthly]
Recruiting PHASE3
-
Dec 2017 — Jan 2018 [monthly]
Recruiting PHASE3
-
Nov 2017 — Dec 2017 [monthly]
Recruiting PHASE3
-
Oct 2017 — Nov 2017 [monthly]
Recruiting PHASE3
-
Sep 2017 — Oct 2017 [monthly]
Recruiting PHASE3
-
Aug 2017 — Sep 2017 [monthly]
Recruiting PHASE3
-
Jul 2017 — Aug 2017 [monthly]
Recruiting PHASE3
-
Jun 2017 — Jul 2017 [monthly]
Recruiting PHASE3
-
May 2017 — Jun 2017 [monthly]
Recruiting PHASE3
-
Apr 2017 — May 2017 [monthly]
Recruiting PHASE3
-
Mar 2017 — Apr 2017 [monthly]
Recruiting PHASE3
-
Feb 2017 — Mar 2017 [monthly]
Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE3
First recorded
Oct 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Merck KGaA, Darmstadt, Germany
- Ono Pharmaceutical Co. Ltd
- Pfizer
- Pierre Fabre Medicament
For direct contact, visit the study record on ClinicalTrials.gov .